2型糖尿病应用罗格列酮前后CRP WBC变化

目的观察应用罗格列酮对2型糖尿病（T2DM）患者体内C反应蛋白（CRP）及白细胞（WBC）水平的影响。方法89例已合用磺脲类和双胍类药物的T2DM患者采用随机、双盲、安慰剂、平行对照方法分至罗格列酮组及安慰剂组，进行3个月的临床观察，治疗前及治疗3个月后分别检测空腹血糖（FPG）、餐后2h血糖（2hPG）、糖化血红蛋白（HbAlc）、胆固醇（TC）、甘油三脂（TG）、低密度脂蛋白（LDL—C）、高密度脂蛋白（HDL—c）、血胰岛素（Fins）、C反应蛋白（CRP）、白细胞计数（WBC），比较各指标的变化，另外选择同期检查的健康志愿者44例作为健康对照组。结果罗格列酮治疗3个月后患者的CRP、WBC出现显著下降（P〈0．01），FPG、2hPG、HbAlc、TG、HOMA—IR亦显著下降（P〈0．05），HDL—C则明显上升（P〈0、05）。结论T2DM患者应用罗格列酮治疗，不仅可以改善其糖脂代谢，还可降低患者体内部分炎症因子的水平。可能对2型糖尿病患者预防慢性并发症有益。

Changes in C- Reactive Protein White Blood Cells Counts in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Rosiglitazone

Objective To observe the changes in serum C-reactive protein(CRP) and white blood cells(WBC) counts in patients with type 2 diabetes mellitus after treatment with rosiglitazone.Methods A 3-month randomized,double-blind placebo controlled study was performed to compare the effect of placebo and rosiglitazone 4mg/d in 89 type 2 diabetic patients who had received sulfonylureas and metformin treatment.Some markers such as fasting plasma glucose(FPG),2h plasma glucose(2hPG),glycosylated hemoglobin(HbA1c),cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),fast insulin(FIns),C-reactive protein(CRP),white blood cells(WBC) counts were measured before and after treatment.In addition,result of simultaneous examination over 44 healthy volunteers was chosen as contrast.Results A significant reduction in CRP,WBC level was observed after 3-month treatment with rosiglitazone(P<0.01).So were FPG,2hPG,HbA1c,TG,and HOMA-IR(P<0.05).But there was a significant increase in HDL-C(P<0.05).Conclusion The use of rosiglitazone in patients with T2DM can not only improve their glucose,blood-lipid metabolism but also decrease the level of some inflammatory makers,and may have possible good effect to preventing complications of the patients with T2DM.